William J. Sandborn - 09 May 2022 Form 4 Insider Report for Ventyx Biosciences, Inc. (VTYX)

Role
President and Chief Medical Officer
Signature
/s/ Christopher Krueger, as Attorney-in-Fact
Issuer symbol
VTYX
Transactions as of
09 May 2022
Net transactions value
$0
Form type
4
Filing time
09 May 2022, 19:06:12 UTC
Next filing
16 Dec 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VTYX Stock Option (right to buy) Award $0 +700,000 $0.000000 700,000 09 May 2022 Common Stock 700,000 $14.85 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, 25% of the shares subject to the option will vest on the one year anniversary of the Vesting Commencement Date (as defined below), and 1/48th of the shares subject to the option will vest ratably each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). "Vesting Commencement Date" shall mean May 9, 2022.

Remarks:

President and Chief Medical Officer